Condition: B-cell Non-Hodgkin Lymphoma · Sponsor: AstraZeneca
This is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL).
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Irvine, California, United States | Recruiting |
| Research Site | Jacksonville, Florida, United States | Recruiting |
| Research Site | Rochester, Minnesota, United States | Recruiting |
| Research Site | New York, New York, United States | Recruiting |
| Research Site | New York, New York, United States | Recruiting |
| Research Site | Cleveland, Ohio, United States | Withdrawn |
| Research Site | Myrtle Beach, South Carolina, United States | Withdrawn |
| Research Site | Franklin, Tennessee, United States | Recruiting |
| Research Site | Melbourne, Australia | Recruiting |
| Research Site | Chengdu, China | Not Yet Recruiting |
| Research Site | Guangzhou, China | Not Yet Recruiting |
| Research Site | Bologna, Italy | Recruiting |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07123454